Portfolio Lab

Xenon Pharmaceuticals Inc.

  • Stock
  • Ticker XENE
  • ISIN CA98420N1050
  • Nasdaq
  • US listing in dollars

Health care · Pharmaceuticals · USA

$37.04 −1.38%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Xenon Pharmaceuticals Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

XENEGlobal equities (VT)

$10,000 grew to $45,728. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −77.7% in 11/2017, measured from the peak in 03/2017. It took 15 months to get back to the old peak.

1-year return
−8.0%
5-year return p.a.
+5.0%
10-year return p.a.
+16.4%
Volatility p.a.
61.9%
Largest decline
−77.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue0.07.50.00.00.00.00.00.0
Operating income-77-73-94-96-110-112-123-120
EBITDA-77-72-94-96-109-112-123-120
Net income-66-65-85-91-105-102-111-110
Earnings per share-0.84-0.83-1.07-1.15-1.31-1.17-1.11-1.11
Balance sheet
Total assets7987436746086331,3871,2961,200
Liabilities4339404851495353
Equity7557046345605821,3381,2421,146
Cash14311713510519954612083
Cash flow
Operating cash flow-54-62-64-72-81-89-95-90
Capital expenditure-0.80.0-0.2-0.3-0.3-0.1-0.3-0.3
Free cash flow-55-62-64-72-82-89-96-91

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2018 at +123.4%, weakest 2017 at −63.3%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
9 Nov 2026−$1.11
6 Aug 2026−$1.11
7 May 2026−$1.17
26 Feb 2026−$1.31
3 Nov 2025−$1.15
11 Aug 2025−$1.07
12 May 2025−$0.83
27 Feb 2025−$0.84
12 Nov 2024−$0.81
8 Aug 2024−$0.75
9 May 2024−$0.62
29 Feb 2024−$0.64

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€3.3bn
Market cap in trading currency
$3.64bn
Enterprise value
$2.69bn
P/E
–
P/S
–
P/B
3.18
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-9.8%

Results (last four quarters)

Revenue
$0
Gross profit
–
EBITDA
−$463m
Net income
−$429m
Earnings per share
−$4.70
Revenue per share
$0.00
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
-50.3%
Return on assets
-35.7%

Balance sheet and cash flow

Cash
$951m
Cash per share
$9.67
Financial debt
–
Debt/equity %
–
Current ratio
21.19
Book value per share
$11.66
Operating cash flow
−$356m
Free cash flow
−$357m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
98.3m
Volume
1.08m
Avg. volume 3 months
1.65m
Relative volume
0.6

Price and technicals

Price
$37.04
1 day
−1.4%
52-week high
$70.96
52-week low
$33.49
Distance to 52-week high
−47.8%
Distance to 52-week low
+10.6%
Distance to 50-day line
−5.1%
Distance to 200-day line
−29.0%
RSI (14)
41
Volatility 1M
37.4%

Performance

1 week
−8.5%
1 month
+1.5%
3 months
−38.8%
6 months
−31.6%
YTD
−17.4%
1 year
−8.9%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has XENE performed since 11/2016?

$10,000 grew to $45,728 by 20 Nov 2026, which is +16.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is XENE?

Volatility was 61.9% per year, measured on monthly returns. The largest decline from a peak was −77.7%, with the low in 11/2017.

How does XENE compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, XENE returned +16.4% at 61.9%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Xenon Pharmaceuticals Inc. (XENE): Return and risk